Subtopic Deep Dive
Atherosclerotic Renovascular Disease
Research Guide
What is Atherosclerotic Renovascular Disease?
Atherosclerotic renovascular disease is renal artery stenosis caused by atherosclerosis leading to ischemic nephropathy and hypertension.
Major trials including ASTRAL (Wheatley 2009, 1161 citations) and CORAL (Cooper et al. 2013, 985 citations) demonstrated no significant benefit of revascularization over medical therapy alone. Doppler ultrasonography predicts poor revascularization outcomes with renal resistance index ≥80 (Radermacher et al. 2001, 772 citations). Conservative management now predominates based on these randomized controlled trials.
Why It Matters
ASTRAL and CORAL trials shifted clinical practice from routine stenting to optimized medical therapy, reducing procedural risks in patients with atherosclerotic renovascular disease (Wheatley 2009; Cooper et al. 2013). This change impacts cardiovascular risk stratification and ischemic nephropathy progression management. Doppler resistance index guides patient selection for interventions, improving outcomes (Radermacher et al. 2001).
Key Research Challenges
Revascularization Benefit Uncertainty
ASTRAL and CORAL trials showed no clinical benefit from stenting over medical therapy despite substantial risks (Wheatley 2009; Cooper et al. 2013). Identifying responders remains difficult. Over 2000 patients analyzed in these RCTs highlight persistent evidence gaps.
Predicting Renal Function Response
Doppler resistance index ≥80 predicts failure of angioplasty or surgery to improve renal function or blood pressure (Radermacher et al. 2001). Limitations include operator dependence and lack of validation in diverse populations. Complementary biomarkers are needed.
Ischemic Nephropathy Progression
Stenting preserves renal size but not always function in chronic insufficiency (Watson et al. 2000). Progression mechanisms involve parenchymal damage beyond stenosis relief. Trials lack long-term data on medical optimization strategies.
Essential Papers
Revascularization versus Medical Therapy for Renal-Artery Stenosis
K Wheatley · 2009 · New England Journal of Medicine · 1.2K citations
We found substantial risks but no evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease. (Current Controlled Trials number, ISRCTN59...
Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis
Christopher J. Cooper, Timothy P. Murphy, Donald E. Cutlip et al. · 2013 · New England Journal of Medicine · 985 citations
Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerot...
Use of Doppler Ultrasonography to Predict the Outcome of Therapy for Renal-Artery Stenosis
Jörg Radermacher, Ajay Chavan, Jörg S. Bleck et al. · 2001 · New England Journal of Medicine · 772 citations
A renal resistance-index value of at least 80 reliably identifies patients with renal-artery stenosis in whom angioplasty or surgery will not improve renal function, blood pressure, or kidney survi...
The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Stella S. Daskalopoulou, Doreen M. Rabi, Kelly B. Zarnke et al. · 2015 · Canadian Journal of Cardiology · 692 citations
Fibromuscular dysplasia
Pierre‐François Plouin, Jérôme Perdu, Agnès La Batide-Alanore et al. · 2007 · Orphanet Journal of Rare Diseases · 281 citations
Fibromuscular dysplasia (FMD), formerly called fibromuscular fibroplasia, is a group of nonatherosclerotic, noninflammatory arterial diseases that most commonly involve the renal and carotid arteri...
Diagnosis, management, and future developments of fibromuscular dysplasia
Jeffrey W. Olin, Brett Sealove · 2011 · Journal of Vascular Surgery · 268 citations
Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia
Ludovic Trinquart, Claire Mounier‐Véhier, Marc Sapoval et al. · 2010 · Hypertension · 259 citations
In patients with fibromuscular dysplasia and renal artery stenosis, renal artery revascularization has been used to cure hypertension or to improve blood pressure control. To provide an up-to-date ...
Reading Guide
Foundational Papers
Read Wheatley (2009) ASTRAL first for RCT establishing no revascularization benefit (1161 citations), then Cooper et al. (2013) CORAL for stenting confirmation (985 citations), followed by Radermacher et al. (2001) Doppler for patient selection (772 citations).
Recent Advances
Study Eirin et al. (2012) on mesenchymal stem cells for ARAS revascularization (258 citations) and Trinquart et al. (2010) FMD efficacy (259 citations) for emerging therapies.
Core Methods
Core techniques include renal artery stenting (Cooper et al. 2013), Doppler resistance index measurement (Radermacher et al. 2001), and comprehensive medical therapy with BP targets (Daskalopoulou et al. 2015).
How PapersFlow Helps You Research Atherosclerotic Renovascular Disease
Discover & Search
Research Agent uses citationGraph on Wheatley (2009) ASTRAL trial to map 1161 citing papers analyzing revascularization failures, then findSimilarPapers uncovers subgroup analyses from CORAL (Cooper et al. 2013). exaSearch queries 'atherosclerotic renovascular disease medical therapy meta-analysis post-CORAL' for recent syntheses beyond OpenAlex.
Analyze & Verify
Analysis Agent applies readPaperContent to extract trial endpoints from Cooper et al. (2013), then verifyResponse with CoVe cross-checks claims against Radermacher et al. (2001) Doppler data. runPythonAnalysis computes GRADE evidence scores for RCTs, performing statistical verification of hazard ratios from ASTRAL via pandas.
Synthesize & Write
Synthesis Agent detects gaps in revascularization predictors post-CORAL using exportMermaid for trial comparison diagrams. Writing Agent employs latexEditText to draft meta-analysis sections, latexSyncCitations for 10+ trial references, and latexCompile for camera-ready review.
Use Cases
"Extract survival data from ASTRAL and CORAL trials for Python meta-analysis"
Research Agent → searchPapers 'ASTRAL CORAL renal stenosis' → Analysis Agent → readPaperContent → runPythonAnalysis (pandas forest plot of HRs) → researcher gets CSV of pooled risk ratios with confidence intervals.
"Write LaTeX review comparing medical vs stenting in ARVD"
Synthesis Agent → gap detection on Wheatley 2009 + Cooper 2013 → Writing Agent → latexEditText (structure sections) → latexSyncCitations → latexCompile → researcher gets compiled PDF with figures and bibliography.
"Find code for Doppler ultrasound resistance index analysis"
Research Agent → searchPapers 'Radermacher Doppler renal resistance' → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets validated Python scripts for RI calculation from Radermacher et al. (2001) implementations.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ ARVD papers starting with citationGraph on Wheatley (2009), generating GRADE-graded report on revascularization evidence. DeepScan applies 7-step CoVe analysis to Radermacher et al. (2001) Doppler methods with statistical checkpoints via runPythonAnalysis. Theorizer workflow synthesizes trial contradictions to hypothesize optimal medical therapy protocols.
Frequently Asked Questions
What defines Atherosclerotic Renovascular Disease?
Atherosclerotic renovascular disease involves renal artery narrowing by atheroma causing hypertension and ischemic nephropathy, distinct from fibromuscular dysplasia.
What do key trials show about revascularization?
ASTRAL (Wheatley 2009) and CORAL (Cooper et al. 2013) found no benefit of stenting over medical therapy for clinical events or renal function.
Which foundational papers to read?
Start with Wheatley (2009, 1161 citations) ASTRAL trial, Cooper et al. (2013, 985 citations) CORAL, and Radermacher et al. (2001, 772 citations) on Doppler prediction.
What are open problems in ARVD research?
Unresolved issues include biomarkers beyond Doppler RI for revascularization response, long-term ischemic nephropathy trajectories, and subgroup benefits in high-risk patients.
Research Renal and Vascular Pathologies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Atherosclerotic Renovascular Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Renal and Vascular Pathologies Research Guide